BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25373410)

  • 61. The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer.
    Navarro A; Tejero R; Viñolas N; Cordeiro A; Marrades RM; Fuster D; Caritg O; Moises J; Muñoz C; Molins L; Ramirez J; Monzo M
    Oncotarget; 2015 Oct; 6(31):31544-56. PubMed ID: 25742785
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Knockdown of fascin-1 expression suppresses cell migration and invasion of non-small cell lung cancer by regulating the MAPK pathway.
    Zhao D; Zhang T; Hou XM; Ling XL
    Biochem Biophys Res Commun; 2018 Mar; 497(2):694-699. PubMed ID: 29458026
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Park KS; Moon YW; Raffeld M; Lee DH; Wang Y; Giaccone G
    Lung Cancer; 2018 Feb; 116():38-45. PubMed ID: 29413049
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.
    Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ
    Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MicroRNA signature predicts survival and relapse in lung cancer.
    Yu SL; Chen HY; Chang GC; Chen CY; Chen HW; Singh S; Cheng CL; Yu CJ; Lee YC; Chen HS; Su TJ; Chiang CC; Li HN; Hong QS; Su HY; Chen CC; Chen WJ; Liu CC; Chan WK; Chen WJ; Li KC; Chen JJ; Yang PC
    Cancer Cell; 2008 Jan; 13(1):48-57. PubMed ID: 18167339
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases.
    Benlloch S; Galbis-Caravajal JM; Alenda C; Peiró FM; Sanchez-Ronco M; Rodríguez-Paniagua JM; Baschwitz B; Rojas E; Massutí B
    Ann Oncol; 2009 Jan; 20(1):91-7. PubMed ID: 18664559
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.
    Misquitta-Ali CM; Cheng E; O'Hanlon D; Liu N; McGlade CJ; Tsao MS; Blencowe BJ
    Mol Cell Biol; 2011 Jan; 31(1):138-50. PubMed ID: 21041478
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression and prognostic roles of TRPV5 and TRPV6 in non-small cell lung cancer after curative resection.
    Fan H; Shen YX; Yuan YF
    Asian Pac J Cancer Prev; 2014; 15(6):2559-63. PubMed ID: 24761864
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
    Jiang W; Fan H; Qian C; Ding J; Wang Q; Pang X
    BMC Cancer; 2016 Jan; 16():16. PubMed ID: 26758745
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.
    Wang Z; Liu T
    Mol Cell Biochem; 2018 Feb; 439(1-2):163-169. PubMed ID: 28861767
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
    Chen C; Peng S; Li P; Ma L; Gan X
    Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.
    Ohtaki Y; Shimizu K; Kaira K; Nagashima T; Obayashi K; Nakazawa S; Kakegawa S; Igai H; Kamiyoshihara M; Nishiyama M; Takeyoshi I
    Surg Today; 2016 Oct; 46(10):1196-208. PubMed ID: 26782692
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.
    Paulsen EE; Kilvaer TK; Rakaee M; Richardsen E; Hald SM; Andersen S; Busund LT; Bremnes RM; Donnem T
    Cancer Immunol Immunother; 2017 Nov; 66(11):1449-1461. PubMed ID: 28707078
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A.
    Ye XY; Xu L; Lu S; Chen ZW
    Int J Immunopathol Pharmacol; 2019; 33():2058738419841481. PubMed ID: 30966836
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.
    Tang XP; Li J; Yu LC; Chen YC; Shi SB; Zhu LR; Chen P
    Lung Cancer; 2013 Aug; 81(2):273-9. PubMed ID: 23756092
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical Significance and Tumor-Suppressive Function of miR-516b in Nonsmall Cell Lung Cancer.
    Zhu J; Zhang Y; Yang X; Jin L
    Cancer Biother Radiopharm; 2017 May; 32(4):115-123. PubMed ID: 28514208
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.